OncoMatch/Clinical Trials/NCT07246668
A Phase II Single-Arm Clinical Study to Evaluate the Efficacy and Safety of Carbon Ion Radiotherapy With Atezolizumab and Bevacizumab Combination Therapy in Patients With Advanced Hepatocellular Carcinoma
Is NCT07246668 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for hepatocellular carcinoma.
This single-center, prospective phase II clinical trial evaluates the safety and therapeutic efficacy of combining carbon ion radiotherapy with the standard first-line regimen of atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma. The study aims to determine whether the addition of carbon ion radiotherapy enhances tumor control and improves clinical outcomes beyond those achieved with systemic therapy alone. Key endpoints include overall survival, progression-free survival, objective response rate, and treatment-related adverse events.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-PD-1 therapy
Prior systemic therapy with anti-PD-1, anti-PD-L1, or anti-VEGF agents within the past year.
Cannot have received: anti-PD-L1 therapy
Prior systemic therapy with anti-PD-1, anti-PD-L1, or anti-VEGF agents within the past year.
Cannot have received: anti-VEGF therapy
Prior systemic therapy with anti-PD-1, anti-PD-L1, or anti-VEGF agents within the past year.
Cannot have received: carbon ion radiotherapy
Exception: to the same anatomical region
Prior carbon ion radiotherapy to the same anatomical region.
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1,500/μL; Platelet count ≥ 75,000/μL; Hemoglobin ≥ 8.5 g/dL
Kidney function
Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL/min
Liver function
AST/ALT ≤ 5 × ULN; Total bilirubin ≤ 3 mg/dL; Child-Pugh class A liver function
Adequate organ and marrow function, including: Absolute neutrophil count ≥ 1,500/μL Platelet count ≥ 75,000/μL Hemoglobin ≥ 8.5 g/dL Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL/min AST/ALT ≤ 5 × ULN Total bilirubin ≤ 3 mg/dL Child-Pugh class A liver function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify